


Healthcare Industry News: HIV/AIDS
News Release - November 1, 2017
Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting
Source: Theravance Biopharma
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
